

asx announcement

Mesoblast Commercial Leadership Featured At World Stem Cell Summit

Melbourne, Australia; 23 September 2008: Australia's regenerative medicine company, Mesoblast Limited (ASX: MSB; USOTC: MBLTY), today announced that its commercial and business activities are being highlighted at The World Stem Cell Summit in Wisconsin, United States, on 23 September 2008.

Executive Director, Professor Silviu Itescu, is a featured speaker at the Summit's investor session entitled "Commercialisation of Stem Cells and Market Trends". A central theme in the presentation is the significant commercial advantage inherent to Mesoblast's allogeneic, or "of-the-shelf", business model for its proprietary adult stem cell technology platform.

A further key focus is on Mesoblast's enhanced business opportunities in the bone repair markets in view of recent concerns by the US Food and Drug Administration (FDA) on the use of Bone Morphogenetic Protein for fusion of the cervical spine. Mesoblast's exceptional safety record and strong clinical results in the fields of spinal fusion and fracture repair serve to highlight the company's competitive advantages in these large global markets.

Mesoblast is one of only a handful of stem cell companies to be featured at The World Stem Cell Summit. According to The World Stem Cell Summit organiser, the US Genetics Policy Institute, the meeting is the pre-eminent gathering for the global stem cell community, bringing together industry leaders, policy-makers, regulators, patient advocates, legal experts, investors, philanthropists and researchers to chart the future of regenerative medicine.

About Mesoblast

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has also acquired 39% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiovascular diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

For further information, please contact:

Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com

